MetLife (MET) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

06.11.25 00:30 Uhr

Werte in diesem Artikel
Aktien

68,39 EUR 1,50 EUR 2,24%

Indizes

PKT PKT

17.794,8 PKT 10,1 PKT 0,06%

3.424,3 PKT 8,3 PKT 0,24%

6.796,3 PKT 24,7 PKT 0,37%

For the quarter ended September 2025, MetLife (MET) reported revenue of $17.9 billion, up 1.6% over the same period last year. EPS came in at $2.34, compared to $1.93 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $18.84 billion, representing a surprise of -5.01%. The company delivered an EPS surprise of +0.43%, with the consensus EPS estimate being $2.33.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how MetLife performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Adjusted Revenue- Asia- Universal life and investment-type product policy fees: $407 million versus $431.68 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -3.1% change.Adjusted Revenue- Corporate & other- Premiums: $11 million versus the three-analyst average estimate of $6 million. The reported number represents a year-over-year change of -283.3%.Adjusted Revenue- Latin America- Other Revenues: $-2 million compared to the $7.53 million average estimate based on three analysts. The reported number represents a change of -122.2% year over year.Adjusted Revenue- Latin America- Net investment income: $414 million versus $442.9 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -4.8% change.Revenue- Premiums: $10.56 billion versus $11.41 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -0.9% change.Revenue- Other Revenues: $724 million versus $653.32 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +11.7% change.Revenue- Universal life and investment-type product policy fees: $1.25 billion compared to the $1.31 billion average estimate based on four analysts. The reported number represents a change of +1.6% year over year.Revenue- Net investment income: $6.09 billion versus $5.47 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +16.5% change.Adjusted Revenue- Retirement & Income Solutions- Premiums: $1.05 billion versus the three-analyst average estimate of $1.77 billion. The reported number represents a year-over-year change of -28%.Adjusted Revenue- Retirement & Income Solutions- Universal life and investment-type product policy fees: $80 million versus $94.27 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +19.4% change.Adjusted Revenue- Retirement & Income Solutions- Net investment income: $2.17 billion versus the three-analyst average estimate of $2.23 billion. The reported number represents a year-over-year change of +1.6%.Adjusted Revenue- Retirement & Income Solutions- Other Revenues: $61 million versus $74.48 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a 0% change.View all Key Company Metrics for MetLife here>>>Shares of MetLife have returned -4% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks Names #1 Semiconductor StockThis under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report MetLife, Inc. (MET): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: MetLife und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf MetLife

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf MetLife

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu MetLife Inc.

Wer­bung

Analysen zu MetLife Inc.

DatumRatingAnalyst
02.01.2018MetLife HoldDeutsche Bank AG
03.11.2017MetLife OutperformRBC Capital Markets
25.05.2017MetLife OutperformFBR & Co.
09.12.2016MetLife HoldStandpoint Research
28.11.2016MetLife Mkt PerformFBR & Co.
DatumRatingAnalyst
03.11.2017MetLife OutperformRBC Capital Markets
25.05.2017MetLife OutperformFBR & Co.
05.05.2016MetLife OutperformRBC Capital Markets
31.07.2015MetLife BuyDeutsche Bank AG
22.06.2015MetLife OutperformRBC Capital Markets
DatumRatingAnalyst
02.01.2018MetLife HoldDeutsche Bank AG
09.12.2016MetLife HoldStandpoint Research
28.11.2016MetLife Mkt PerformFBR & Co.
13.07.2016MetLife HoldDeutsche Bank AG
15.03.2016MetLife NeutralUBS AG
DatumRatingAnalyst
04.12.2006Update MetLife Inc.: UnderperformFriedman, Billings Ramsey & Co
14.09.2005MetLife DowngradeDeutsche Securities
14.09.2005Update MetLife Inc.: SellDeutsche Securities

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für MetLife Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen